SUP-B15Homo sapiens (Human)Cancer cell line

Also known as: SupB15WT, SupB15W, SupB15, SUPB15, SUPB-15, Sup-B15

🤖 AI SummaryBased on 11 publications

Quick Overview

Human B-cell leukemia cell line with BCR-ABL fusion

Detailed Summary

SUP-B15 is a human B-cell leukemia cell line derived from a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). It is characterized by the presence of the BCR-ABL fusion gene, which results from the t(9;22)(q34;q11) translocation. This cell line is widely used in research to study the molecular mechanisms of BCR-ABL-mediated leukemogenesis and to evaluate therapeutic strategies targeting the BCR-ABL tyrosine kinase. The cell line exhibits specific genetic and molecular features that make it a valuable model for understanding the pathogenesis of Philadelphia chromosome-positive leukemias.

Research Applications

Study of BCR-ABL fusion gene and its role in leukemogenesisEvaluation of tyrosine kinase inhibitors targeting BCR-ABLInvestigation of molecular mechanisms of Philadelphia chromosome-positive leukemias

Key Characteristics

Presence of BCR-ABL fusion genePhiladelphia chromosome-positiveDerived from B-cell lineage

Generated on 6/14/2025

Basic Information

Database ID	CVCL_0103
Species	Homo sapiens (Human)
Tissue Source	Bone marrow[UBERON:UBERON_0002371]

Donor Information

Age	9
Age Category	Pediatric
Sex	Male
Race	caucasian
Subtype Features	BCR-ABL1

Disease Information

Disease	B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)
Lineage	Lymphoid
Subtype	B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2);BCR-ABL1
OncoTree Code	BLLBCRABL1

DepMap Information

Source Type	ATCC
Source ID	ACH-000059_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
Gene fusion	ABL1	BCR-ABL1, BCR-ABL	-	BCR exon 1 fused to ABL1 exon 2	PubMed=10576511, PubMed=10071072, PubMed=8751477

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X,Y

CSF1PO

11,12

D13S317

8,14

D16S539

11,12

D18S51

D19S433

13,15

D21S11

28,31

D2S1338

20,23

D3S1358

15,16

D5S818

12,13

D7S820

10,11

D8S1179

11,14

FGA

19,20

Penta D

9,12

Penta E

TH01

6,9.3

TPOX

8,9

vWA

15,17

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOI PubMed PMC

Integrative multi-omics and drug response profiling of childhood acute lymphoblastic leukemia cell lines.

Lehtio J., Vesterlund M., Jafari R.

Nat. Commun. 13:1691.1-1691.19(2022).

DOI PubMed PMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOI PubMed PMC

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOI PubMed PMC

EZH2 inhibition in Ewing sarcoma upregulates GD2 expression for targeting with gene-modified T cells.

Muller I., Walles H., Hartmann W., Rossig C.

Mol. Ther. 27:933-946(2019).

DOI PubMed PMC

Screening human cell lines for viral infections applying RNA-Seq data analysis.

Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.

PLoS ONE 14:E0210404-E0210404(2019).

DOI PubMed PMC

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

Yang H.H., Koeffler H.P.

BMC Cancer 18:940.1-940.13(2018).

DOI PubMed PMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOI PubMed PMC

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOI PubMed PMC

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOI PubMed

Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation.

Bassani-Sternberg M., Pletscher-Frankild S., Jensen L.J., Mann M.

Mol. Cell. Proteomics 14:658-673(2015).

DOI PubMed PMC

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

DOI PubMed

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOI PubMed PMC

JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.

Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.

Leukemia 20:471-476(2006).

DOI PubMed

Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations.

Fioretos T.

Leukemia 19:1042-1050(2005).

DOI PubMed

ABL-BCR expression in BCR-ABL-positive human leukemia cell lines.";

Uphoff C.C., Habig S., Fombonne S., Matsuo Y., Drexler H.G.

Leuk. Res. 23:1055-1060(1999).

DOI PubMed

Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia.

Drexler H.G., MacLeod R.A.F., Uphoff C.C.

Leuk. Res. 23:207-215(1999).

DOI PubMed

Sensitivity to Fas-mediated apoptosis in pediatric acute lymphoblastic leukemia is associated with a mutant p53 phenotype and absence of Bcl-2 expression.

Zhou M.-X., Gu L.-B., Yeager A.M., Findley H.W. Jr.

Leukemia 12:1756-1763(1998).

DOI PubMed

Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia.

Findley H.W. Jr., Gu L.-B., Yeager A.M., Zhou M.-X.

Blood 89:2986-2993(1997).

DOI PubMed

Occurrence of TEL-AML1 fusion resulting from (12;21) translocation in human early B-lineage leukemia cell lines.

Janssen J.W.G., Drexler H.G.

Leukemia 11:441-447(1997).

DOI PubMed

TEL-AML1 translocations with TEL and CDKN2 inactivation in acute lymphoblastic leukemia cell lines.

Giordano L., Gupta R., Fears S., Nucifora G., Rowley J.D., Smith S.D.

Blood 88:785-794(1996).

DOI PubMed

Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene.

Zhou M.-X., Yeager A.M., Smith S.D., Findley H.W. Jr.

Blood 85:1608-1614(1995).

DOI PubMed

Homozygous deletions of the CDKN2 (MTS1/p16ink4) gene in cell lines established from children with acute lymphoblastic leukemia.

Findley H.W. Jr.

Leukemia 9:1159-1161(1995).

PubMed

Philadelphia chromosome-positive acute lymphoblastic leukemia cell lines without classical breakpoint cluster region rearrangement.

Naumovski L., Morgan R., Hecht F., Link M.P., Glader B.E., Smith S.D.

Cancer Res. 48:2876-2879(1988).

PubMed

The leukemia-lymphoma cell line factsbook.";

Drexler H.G.

(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).

DOI